Dabigatran etexilate is a new oral anticoagulant for the prevention of stroke or systemic embolism in adult patients with non-valvular atrial fibrillation (AF) and at least one risk factor for stroke. With a fast onset of action and a predictable anticoagulant effect , it has practical advantages over vit. K antagonists in clinical practice.
Dosage:75 mg bid dose ofdabi atran is ap roved for use in patients with CrCL .
Capsule
مرتان يوميا
87 EGP
Dabigatran etexilate is a new oral anticoagulant for the prevention of stroke or systemic embolism in adult patients with non-valvular atrial fibrillation (AF) and at least one risk factor for stroke. With a fast onset of action and a predictable anticoagulant effect , it has practical advantages over vit. K antagonists in clinical practice.
Dosage:75 mg bid dose ofdabi atran is ap roved for use in patients with CrCL .
Note: All the provided information about this drug does not substitute for consulting a doctor.